Geriatrics photo quiz. Coronary Occlusion.

J. Shua-Haim,N. Kothari,J. Ross

1999-02-01

Geriatrics

Abstract:

What problem does this paper attempt to address?

Multi-Omics Integration in Mice With Parkinson’s Disease and the Intervention Effect of Cyanidin-3-O-Glucoside

Wang Wang,Guoxue Zhu,Yuwen Wang,Wei Li,Shilin Yi,Kai Wang,Lu Fan,Juanjuan Tang,Ruini Chen

DOI: https://doi.org/10.3389/fnagi.2022.877078

IF: 4.8

2022-04-29

Frontiers in Aging Neuroscience

Abstract:Background Parkinson’s disease (PD) is a multifactorial degenerative disease of the central nervous system, which affects mostly older adults. To date, research has focused on the progression of PD. Simultaneously, it was confirmed that the imbalances in gut microbiota are associated with the onset and progression of PD. Accurate diagnosis and precise treatment of PD are currently deficient due to the absence of effective biomarkers. Methods In this study, the pharmacodynamic study of cyanidin-3- O -glucoside in PD mice was used. It intends to use the “imbalance” and “balance” of intestinal microecology as the starting point to investigate the “gut-to-brain” hypothesis using metabolomic-combined 16S rRNA gene sequencing methods. Simultaneously, metabolomic analysis was implemented to acquire differential metabolites, and microbiome analysis was performed to analyze the composition and filter the remarkably altered gut microbiota at the phylum/genera level. Afterward, metabolic pathway and functional prediction analysis of the screened differential metabolites and gut microbiota were applied using the MetaboAnalyst database. In addition, Pearson’s correlation analysis was used for the differential metabolites and gut microbiota. We found that cyanidin-3- O -glucoside could protect 1-methyl-4-phenyl-1,2,3,6− tetrahydropy ridine (MPTP)-induced PD mice. Results Metabolomic analysis showed that MPTP-induced dysbiosis of the gut microbiota significantly altered sixty-seven metabolites. The present studies have also shown that MPTP-induced PD is related to lipid metabolism, amino acid metabolism, and so on. The 16S rRNA sequencing analysis indicated that 5 phyla and 22 genera were significantly altered. Furthermore, the differential gut microbiota was interrelated with amino acid metabolism, and so on. The metabolites and gut microbiota network diagram revealed significant correlations between 11 genera and 8 differential metabolites. Conclusion In combination, this study offers potential molecular biomarkers that should be validated for future translation into clinical applications for more accurately diagnosing PD. Simultaneously, the results of this study lay a basis for further study of the association between host metabolisms, gut microbiota, and PD.

neurosciences,geriatrics & gerontology,gerontology
Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Zhuo Li,Gang Lu,Enli Luo,Bin Wu,Zhe Li,Jianwen Guo,Zhangyong Xia,Chunye Zheng,Qiaozhen Su,Yan Zeng,Wai Yee Chan,Xianwei Su,Xinmin Qiu,Xirun Zheng,Qiaodi Cai,Yanjuan Xu,Yingjun Chen,Yuzhen Fan,Weiwei Chen,Zecheng Yu,Xinjie Chen,Chunying Zheng,Mingbang Wang,Wai Sang Poon,Xiaodong Luo

DOI: https://doi.org/10.1016/j.neuroscience.2021.10.011

IF: 3.708

2022-01-01

Neuroscience

Abstract:Parkinson's disease (PD) is the second most frequently diagnosed neurodegenerative disease. The purpose of this study was to investigate the link between microbiota composition in important mucosal interfaces (oral, nasal, and intestinal) and PD. Sequencing was undertaken of the V4-V5 region of the 16S ribosomal RNA (rRNA) gene of the microbiome from the oral cavity, nasal cavity, and gut of 91 PD patients and 91 healthy controls. Significant differences were found in microbiota composition in the oral cavity and gut, but not the nasal cavity, between PD patients and healthy controls after adjusting for age, gender, and body mass index (BMI). More genera in the oral cavity were significantly positively correlated with clinical characteristics, such as the HAMA and HAMD rating scales. The taxa c_Clostridia, o_Clostridiales, and f_Ruminococcaceae in the gut microbiota were associated with weight and MMSE score. Furthermore, as a result of dysbiosis, there was an enrichment of ion channel-, oxidative phosphorylation-, and carbohydrate metabolism-related pathways in the oral cavity and glycolysis/gluconeogenesis- and propanoate metabolism-related pathways in the intestine. Changes in these pathways can influence metabolism and inflammation, thereby contributing to PD pathogenesis. In addition, several subnetworks containing differentially abundant microbiota in the oral cavity and gut samples from PD patients may regulate microbial composition and function in PD. Overall, our results indicate that oral and gut dysbiosis may affect PD progression and provide a basis for understanding the pathogenesis of PD and identifying potential therapeutic targets for the treatment of this disease.
Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease

Zhuo Li,Gang Lu,Zhe Li,Bin Wu,Enli Luo,Xinmin Qiu,Jianwen Guo,Zhangyong Xia,Chunye Zheng,Qiaozhen Su,Yan Zeng,Wai Yee Chan,Xianwei Su,Qiaodi Cai,Yanjuan Xu,Yingjun Chen,Mingbang Wang,Wai Sang Poon,Xiaodong Luo

DOI: https://doi.org/10.3389/fimmu.2021.632482

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:Recent evidence suggests that inflammation was participated in the pathogenesis of PD, thus, to understand the potential mechanism of gut microbiota in the pathogenesis of Parkinson's disease (PD), we performed a metagenomic analysis of fecal samples from PD patient and controls. Using a two-stage metagenome-wide association strategy, fecal DNA samples from 69 PD patients and 244 controls in three groups (comprising 66 spouses, 97 age-matched, and 81 normal samples, respectively) were analyzed, and differences between candidate gut microbiota and microbiota-associated epitopes (MEs) were compared. In the study, 27 candidate bacterial biomarkers and twenty-eight candidate epitope peptides were significantly different between the PD patients and control groups. Further, enriched 4 and 13 MEs in PD were positively associated with abnormal inflammatory indicators [neutrophil percentage (NEUT.1), monocyte count/percentage (MONO/MONO.1), white blood cell count (WBC)] and five candidate bacterial biomarkers (c_Actinobacteria, f_Bifidobacteriaceae, g_Bifidobacterium, o_Bifidobacteriales, p_Actinobacteria) from Actinobacteria phylum, and they were also positively associated with histidine degradation and proline biosynthesis pathways, respectively. Additionally, enriched 2 MEs and 1 ME in PD were positively associated with above inflammatory indicators and two bacteria (f_Lactobacillaceae, g_Lactobacillus) from Firmicutes phylum, and they were also positively associated with pyruvate fermentation to propanoate I and negatively associated with isopropanol biosynthesis, respectively. Of these MEs, two MEs from GROEL2, RPSC were derived from Mycobacterium tuberculosis, triggered the T cell immune response, as previously reported. Additionally, other candidate epitope peptides derived from Mycobacterium tuberculosis and Mycobacterium leprae may also have potential immune effects in PD. In all, the altered MEs in PD may relate to abnormalities in immunity and glutamate and propionate metabolism, which furthers our understanding of the pathogenesis of PD.
Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease

Avril Metcalfe-Roach,Mihai S Cirstea,Adam C Yu,Hena R Ramay,Olabisi Coker,Seti Boroomand,Faezeh Kharazyan,Davide Martino,Laura K Sycuro,Silke Appel-Cresswell,B Brett Finlay

DOI: https://doi.org/10.1002/mds.29959

2024-08-28

Abstract:Background: Parkinson's disease (PD) has been consistently linked to alterations within the gut microbiome. Objective: Our goal was to identify microbial features associated with PD incidence and progression. Methods: Metagenomic sequencing was used to characterize taxonomic and functional changes to the PD microbiome and to explore their relation to bacterial metabolites and disease progression. Motor and non-motor symptoms were tracked using Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and levodopa equivalent dose across ≤5 yearly study visits. Stool samples were collected at baseline for metagenomic sequencing (176 PD, 100 controls). Results: PD-derived stool samples had reduced intermicrobial connectivity and seven differentially abundant species compared to controls. A suite of bacterial functions differed between PD and controls, including depletion of carbohydrate degradation pathways and enrichment of ribosomal genes. Faecalibacterium prausnitzii-specific reads contributed significantly to more than half of all differentially abundant functional terms. A subset of disease-associated functional terms correlated with faster progression of MDS-UPDRS part IV and separated those with slow and fast progression with moderate accuracy within a random forest model (area under curve = 0.70). Most PD-associated microbial trends were stronger in those with symmetric motor symptoms. Conclusion: We provide further evidence that the PD microbiome is characterized by reduced intermicrobial communication and a shift to proteolytic metabolism in lieu of short-chain fatty acid production, and suggest that these microbial alterations may be relevant to disease progression. We also describe how our results support the existence of gut-first versus brain-first PD subtypes. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Development of a Telemedicine model with low cost portable tool kit for remote diagnosis of rural people in Bangladesh

U. K. Prodhan,Mohammad Zahidur Rahman,Ahsin Abid,Mohtasim Bellah

DOI: https://doi.org/10.1109/ICISET.2016.7856513

2016-10-01

Abstract:In this paper we have developed a Telemedicine model with portable tool kit for remote patients to collect vital signs of patients which are used for Telemedicine services. This developed system is low cost, portable, and easily maintainable and can be integrated with any complex health system. We have used the GNU health where local doctors can communicate with a low cost terminal. Expert doctors can also take part through this terminal and deliver treatment to the patients. The patient's medical history is stored in GNU health database and accessed from the remote terminal. We have successfully designed the system and collected the patient's data. Through our developed android apps, the data will be stored in the staging server. From the staging server, any health system can collect the data and give the services to the rural people. Finally we can conclude that, Telemedicine service can be given effectively by using our portable tool kit in a cost effective manner which improves the quality and accessibility especially in rural areas.
MPTP Induced Parkinson's Disease in Mouse: Potential Association Between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis.

Yuanhui Zhu,Fei Huan,Junfeng Wang,Xuexue Xie,Guoqin Yu,Xi Wang,Lei Jiang,Rong Gao,Hang Xiao,Haixia Ding,Jun Wang

DOI: https://doi.org/10.1021/acschemneuro.0c00475

2020-01-01

ACS Chemical Neuroscience

Abstract:Recent studies have revealed significant roles of the neurotransmitters and gut microbiota along the gut-brain axis in Parkinson's disease (PD), however, the potential mechanisms remain poorly understood. In the current study, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced a characteristic PD neurobehavior changes accompanied by increased α-synuclein, apoptotic protein Bim, cleaved caspase-3 and decreased expression of tyrosine hydroxylase (TH). Meanwhile, the tryptophan (TRP) and tyrosine (TYR) neurotransmitter metabolites involving kynurenine (KYN), serotonin (5-HT) and dopamine (DA) pathways were significantly changed in serum. Furthermore, the step-limited enzymes which responsible for the key metabolic pathways of these neurotransmitters were obviously dysregulated. The 16S rRNA gene sequence results indicated that the abundance and diversity of the microbiota were obviously decreased in MPTP treated mice, the presence of Ruminococcus, Parabacteroides and Parasutterella families were obviously increased while Coriobacteriaceae, Flavonifractor, Lachnospiraceae, Lactobacillaceae and Rikenellaceae abundance was markedly decreased. The connectivity between the gut microbiota and neurotransmitter metabolism revealed that the gut microbiota dysbiosis was associated with the disturbance of the DA, KYN and 5-HT metabolic pathways. Therefore, our results provide the evidence that the gut-microbiota-brain axis disturbance may play an important role in PD development, and targeting this axis might provide a promising therapeutic strategy for PD. Key Words: gut-microbiota-brain axis; gut microbiota dysbiosis; neurotransmitter metabolism; Parkinson's disease.
Maximizing communication opportunity for collaborative spectrum sensing in cognitive radio networks

T. Nishida,Masahiro Sasabe,S. Kasahara

DOI: https://doi.org/10.1109/ATNAC.2017.8215373

2017-11-01

Abstract:In cognitive radio networks, secondary users (SUs) must accurately sense the spectrum of primary user (PU) to acquire their own communication opportunities without interfering PU's communication. Collaborative spectrum sensing (CSS) among SUs can improve the probability to detect PU's communication, compared to non-collaborative spectrum sensing, where each SU senses signal independently. In this paper, we propose a communication opportunity maximization scheme for CSS in multiple PUs cognitive radio networks. First, we define an objective function that represents SU's communication opportunity and a constraint on miss detection probability. In the proposed scheme, each SU forms a group with other SUs to meet the constraint and maximize its own communication opportunity according to the objective function and the constraint. Through simulation experiments with a two-PU scenario, we show that the proposed scheme can improve the ratio of winning SUs, that can use PU's channel, to the whole SUs, in comparison with the non-collaborative spectrum sensing. We also show that it can quickly increase the overall throughput of winning SUs up to the theoretical upper bound.
Identification of gut metabolites associated with Parkinson's disease using bioinformatic analyses

Jun Yan,Xia Feng,Xia Zhou,Mengjie Zhao,Hong Xiao,Rui Li,Hong Shen

DOI: https://doi.org/10.3389/fnagi.2022.927625

IF: 4.8

2022-07-27

Frontiers in Aging Neuroscience

Abstract:Background: Parkinson's disease (PD) is a common neurodegenerative disease affecting the movement of elderly patients. Environmental exposures are the risk factors for PD; however, gut environmental risk factors for PD are critically understudied. The proof-of-concept study is to identify gut metabolites in feces, as environmental exposure risk factors, that are associated with PD and potentially increase the risk for PD by using leverage of known toxicology results. Materials and methods: We collected the data regarding the gut metabolites whose levels were significantly changed in the feces of patients with PD from the original clinical studies after searching the following databases: EBM Reviews, PubMed, Embase, MEDLINE, and Elsevier ClinicalKey. We further searched each candidate metabolite-interacting PD gene set by using the public Comparative Toxicogenomics Database (CTD), identified and validated gut metabolites associated with PD, and determined gut metabolites affecting specific biological functions and cellular pathways involved in PD by using PANTHER tools. Results: Sixteen metabolites were identified and divided into the following main categories according to their structures and biological functions: alcohols (ethanol), amino acids (leucine, phenylalanine, pyroglutamic acid, glutamate, and tyrosine), short-chain fatty acids (propionate and butyrate), unsaturated fatty acids (linoleic acid and oleic acid), energy metabolism (lactate, pyruvate, and fumarate), vitamins (nicotinic acid and pantothenic acid), and choline metabolism (choline). Finally, a total of three identified metabolites, including butyrate, tyrosine, and phenylalanine, were validated that were associated with PD. Conclusion: Our findings identified the gut metabolites that were highly enriched for PD genes and potentially increase the risk of developing PD. The identification of gut metabolite exposures can provide biomarkers for disease identification, facilitate an understanding of the relationship between gut metabolite exposures and response, and present an opportunity for PD prevention and therapies.

neurosciences,geriatrics & gerontology,gerontology
Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Yiting Ni,Qiaowen Tong,Mengying Xu,Jiayi Gu,Hua Ye

DOI: https://doi.org/10.1007/s12035-024-04370-7

2024-08-12

Abstract:Recent insights into Parkinson's disease (PD), a progressive neurodegenerative disorder, suggest a significant influence of the gut microbiome on its pathogenesis and progression through the gut-brain axis. This study integrates 16S rRNA sequencing, high-throughput transcriptomic sequencing, and animal model experiments to explore the molecular mechanisms underpinning the role of gut-brain axis in PD, with a focus on short-chain fatty acids (SCFAs) mediated by the SCFA receptors FFAR2 and FFAR3. Our findings highlighted prominent differences in the gut microbiota composition between PD patients and healthy individuals, particularly in taxa such as Escherichia_Shigella and Bacteroidetes, which potentially impact SCFA levels through secondary metabolite biosynthesis. Notably, fecal microbiota transplantation (FMT) from healthy to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse models significantly improved motor function, enhanced dopamine and serotonin levels in the striatum, and increased the number of dopaminergic neurons in the substantia nigra while reducing glial cell activation. This therapeutic effect was associated with increased levels of SCFAs such as acetate, propionate, and butyrate in the gut of MPTP-lesioned mice. Moreover, transcriptomic analyses revealed upregulated expression of FFAR2 and FFAR3 in MPTP-lesioned mice, indicating their crucial role in mediating the benefits of FMT on the central nervous system. These results provide compelling evidence that gut microbiota and SCFAs play a critical role in modulating the gut-brain axis, offering new insights into PD's etiology and potential targets for therapeutic intervention.
Microbial Biomarker Discovery in Parkinson’s Disease Through a Network-Based Approach

Zhe Zhao,Jing Chen,Danhua Zhao,Baoyu Chen,Qi Wang,Yuan Li,Junyi Chen,Chaobo Bai,Xintong Guo,Nan Hu,Bingwei Zhang,Rongsheng Zhao,Junliang Yuan

DOI: https://doi.org/10.1038/s41531-024-00802-2

2024-01-01

npj Parkinson s Disease

Abstract:Associations between the gut microbiota and Parkinson’s disease (PD) have been widely investigated. However, the replicable biomarkers for PD diagnosis across multiple populations remain elusive. Herein, we performed a meta-analysis to investigate the pivotal role of the gut microbiome in PD and its potential diagnostic implications. Six 16S rRNA gene amplicon sequence datasets from five independent studies were integrated, encompassing 550 PD and 456 healthy control samples. The analysis revealed significant alterations in microbial composition and alpha and beta diversity, emphasizing altered gut microbiota in PD. Specific microbial taxa, including Faecalibacterium, Roseburia, and Coprococcus_2, known as butyrate producers, were notably diminished in PD, potentially contributing to intestinal inflammation. Conversely, genera such as Akkermansia and Bilophila exhibited increased relative abundances. A network-based algorithm called NetMoss was utilized to identify potential biomarkers of PD. Afterwards, a classification model incorporating 11 optimized genera demonstrated high performance. Further functional analyses indicated enrichment in pathways related to neurodegeneration and metabolic pathways. These findings illuminate the intricate relationship between the gut microbiota and PD, offering insights into potential therapeutic interventions and personalized diagnostic strategies.
Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance

Mingxia Bi,Lijuan Feng,Jiahui He,Chang Liu,Yulin Wang,Hong Jiang,Shuang-Jiang Liu

DOI: https://doi.org/10.1016/j.arr.2022.101759

IF: 11.788

2022-12-01

Ageing Research Reviews

Abstract:Parkinson’s disease (PD) is a complicated neurodegenerative disease, of which gastrointestinal disturbance appears prior to motor symptoms. Numerous studies have shed light on the roles of gastrointestinal tract and its neural connection to brain in PD pathology. In the past decades, the fields of microbiology and neuroscience have become ever more entwined. The emergence of gut microbiome has been considered as one of the key regulators of gut-brain function. With the advent of multi-omics sequencing techniques, gut microbiome of PD patients has been shown unique characteristics. The resident gut microbiota can exert considerable effects in PD and there are suggestions of a link between gut microbiome dysbiosis and PD progression. In this review, we summarize the latest progresses of gut microbiome dysbiosis in PD pathogenesis, further highlight the clinical relevance of gut microbiota and its metabolites in both the non-motor and motor symptoms of PD. Furthermore, we draw attention to the complex interplay between gut microbiota and PD drugs, with the purpose of improving drug efficacy and prescription accordingly. Further studies at specific strain level and longitudinal prospective clinical trials using optimized methods are still needed for the development of diagnostic markers and novel therapeutic regimens for PD.

cell biology,geriatrics & gerontology,gerontology
Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease

Mihai S. Cirstea,Adam C. Yu,Ella Golz,Kristen Sundvick,Daniel Kliger,Nina Radisavljevic,Liam H. Foulger,Melissa Mackenzie,Tau Huan,B. Brett Finlay,Silke Appel‐Cresswell

DOI: https://doi.org/10.1002/mds.28052

IF: 9.698

2020-05-01

Movement Disorders

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Parkinson's disease is characterized by a high burden of gastrointestinal comorbidities, especially constipation and reduced colonic transit time, and by gut microbiota alterations. The diverse metabolites produced by the microbiota are broadly relevant to host health. How microbiota composition and metabolism relate to gastrointestinal function in Parkinson's disease is largely unknown. The objectives of the current study were to assesses associations between microbiota composition, stool consistency, constipation, and systemic microbial metabolites in Parkinson's disease to better understand how intestinal microbes contribute to gastrointestinal disturbances commonly observed in patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Three hundred participants (197 Parkinson's patients and 103 controls) were recruited for this cross‐sectional cohort study. Participants supplied fecal samples for microbiota sequencing (n = 300) and serum for untargeted metabolomics (n = 125). Data were collected on motor and nonmotor Parkinson's symptoms, medications, diet, and demographics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Significant microbiota taxonomic differences were observed in Parkinson's patients, even when controlling for gastrointestinal function. Parkinson's microbiota was characterized by reduced carbohydrate fermentation and butyrate synthesis capacity and increased proteolytic fermentation and production of deleterious amino acid metabolites, including p‐cresol and phenylacetylglutamine. Taxonomic shifts and elevated proteolytic metabolites were strongly associated with stool consistency (a proxy for colonic transit time) and constipation among patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Compositional and metabolic alterations in the Parkinson's microbiota are highly associated with gut function, suggesting plausible mechanistic links between altered bacterial metabolism and reduced gut health in this disease. The systemic detection of elevated deleterious proteolytic microbial metabolites in Parkinson's serum suggests a mechanism whereby microbiota dysbiosis contributes to disease etiology and pathophysiology. © 2020 International Parkinson and Movement Disorder Society</p></section>

clinical neurology
Cross-Sectional Study on the Gut Microbiome of Parkinson’s Disease Patients in Central China

Liangwei Mao,Yu Zhang,Jing Tian,Ming Sang,Guimin Zhang,Yuling Zhou,Puqing Wang

DOI: https://doi.org/10.3389/fmicb.2021.728479

IF: 5.2

2021-09-28

Frontiers in Microbiology

Abstract:Gastrointestinal dysfunction plays an important role in the occurrence and development of Parkinson’s disease (PD). This study investigates the composition of the gut microbiome using shotgun metagenomic sequencing in PD patients in central China. Fecal samples from 39 PD patients (PD group) and the corresponding 39 healthy spouses of the patients (SP) were collected for shotgun metagenomics sequencing. Results showed a significantly altered microbial composition in the PD patients. Bilophila wadsworthia enrichment was found in the gut microbiome of PD patients, which has not been reported in previous studies. The random forest (RF) model, which identifies differences in microbiomes, reliably discriminated patients with PD from controls; the area under the receiver operating characteristic curve was 0.803. Further analysis of the microbiome and clinical symptoms showed that Klebsiella and Parasutterella were positively correlated with the duration and severity of PD, whereas hydrogen-generating Prevotella was negatively correlated with disease severity. The Cluster of Orthologous Groups of protein database, the KEGG Orthology database, and the carbohydrate-active enzymes of gene-category analysis showed that branched-chain amino acid–related proteins were significantly increased, and GH43 was significantly reduced in the PD group. Functional analysis of the metagenome confirmed differences in microbiome metabolism in the PD group related to short-chain fatty acid precursor metabolism.

microbiology
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Yaping Shao,Tianbai Li,Zheyi Liu,Xiaolin Wang,Xiaojiao Xu,Song Li,Guowang Xu,Weidong Le

DOI: https://doi.org/10.1186/s13024-021-00425-8

2021-01-23

Molecular Neurodegeneration

Abstract:Abstract Background Parkinson’s disease (PD) is a prevalent neurological disease in the elderly with increasing morbidity and mortality. Despite enormous efforts, rapid and accurate diagnosis of PD is still compromised. Metabolomics defines the final readout of genome-environment interactions through the analysis of the entire metabolic profile in biological matrices. Recently, unbiased metabolic profiling of human sample has been initiated to identify novel PD metabolic biomarkers and dysfunctional metabolic pathways, however, it remains a challenge to define reliable biomarker(s) for clinical use. Methods We presented a comprehensive metabolic evaluation for identifying crucial metabolic disturbances in PD using liquid chromatography-high resolution mass spectrometry-based metabolomics approach. Plasma samples from 3 independent cohorts ( n = 460, 223 PD, 169 healthy controls (HCs) and 68 PD-unrelated neurological disease controls) were collected for the characterization of metabolic changes resulted from PD, antiparkinsonian treatment and potential interferences of other diseases. Unbiased multivariate and univariate analyses were performed to determine the most promising metabolic signatures from all metabolomic datasets. Multiple linear regressions were applied to investigate the associations of metabolites with age, duration time and stage of PD. The combinational biomarker model established by binary logistic regression analysis was validated by 3 cohorts. Results A list of metabolites including amino acids, acylcarnitines, organic acids, steroids, amides, and lipids from human plasma of 3 cohorts were identified. Compared with HC, we observed significant reductions of fatty acids (FFAs) and caffeine metabolites, elevations of bile acids and microbiota-derived deleterious metabolites, and alterations in steroid hormones in drug-naïve PD. Additionally, we found that L-dopa treatment could affect plasma metabolome involved in phenylalanine and tyrosine metabolism and alleviate the elevations of bile acids in PD. Finally, a metabolite panel of 4 biomarker candidates, including FFA 10:0, FFA 12:0, indolelactic acid and phenylacetyl-glutamine was identified based on comprehensive discovery and validation workflow. This panel showed favorable discriminating power for PD. Conclusions This study may help improve our understanding of PD etiopathogenesis and facilitate target screening for therapeutic intervention. The metabolite panel identified in this study may provide novel approach for the clinical diagnosis of PD in the future.

neurosciences
Female adolescents at high, moderate, and low risk of exposure to HIV: differences in knowledge, beliefs, and behavior.

S. Millstein,A. Moscicki,J. Broering

DOI: https://doi.org/10.1016/1054-139X(94)90540-1

IF: 7.898

1994-03-01

Journal of Adolescent Health

Abstract:
Gut bacterial profiles in Parkinson's disease: A systematic review

Zhe Li,Hongfeng Liang,Yingyu Hu,Lin Lu,Chunye Zheng,Yuzhen Fan,Bin Wu,Tao Zou,Xiaodong Luo,Xinchun Zhang,Yan Zeng,Ziyan Liu,Zhicheng Zhou,Zhenyu Yue,Yi Ren,Zhuo Li,Qiaozhen Su,Pingyi Xu

DOI: https://doi.org/10.1111/cns.13990

2022-10-27

Abstract:The role of gut bacteria in association with Parkinson's disease (PD) may involve the alterations of bacteria with the capacity to produce short‐chain fatty acids (SCFAs) and an increase in putative pathobionts, which may work together to potentially impair the intestinal barrier and/or blood–brain barrier integrity, stimulating systemic and neural inflammation. SCFAs‐producing bacteria may reduce or increase outside of an "optimal range". Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, the increased Bifidobacterium and Lactobacillus may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging. Introduction Recent advances have highlighted the relationships between gut dysbiosis and Parkinson's disease (PD). Microbiota transplantation from PD patients to mice can induce increased alpha‐synuclein‐mediated motor deficits. Human studies have identified differences in the gut microbiota of PD patients compared to healthy controls. We undertook a systematic review to evaluate the available evidence for the involvement of gut bacteria in the etiology of PD. Methods The PubMed databank, the China National Knowledge Infrastructure databank, and Wanfang Data were searched from inception until June 2021 to identify human case–control studies that investigated relationships between PD and microbiota quantified from feces. We evaluated the resulting studies focusing on bacterial taxa that were different between PD patients and healthy controls. Results Twenty‐six studies were found in which 53 microbial families and 98 genera exhibited differences between patients with PD and healthy controls. The genera identified by more than two studies as increased in PD were Bifidobacterium, Alistipes, Christensenella, Enterococcus, Oscillospira, Bilophila, Desulfovibrio, Escherichia/Shigella, and Akkermansia, while Prevotella, Blautia, Faecalibacterium, Fusicatenibacter, and Haemophilus had three or more reports of being lower in PD patients. More than one report demonstrated that Bacteroides, Odoribacter, Parabacteroides, Butyricicoccus, Butyrivibrio, Clostridium, Coprococcus, Lachnospira, Lactobacillus, Megasphaera, Phascolarctobacterium, Roseburia, Ruminococcus, Streptococcus, and Klebsiella were altered in both directions. Conclusion Our review shows that the involvement of the gut microbiome in the etiology of PD may involve alterations of short‐chain fatty acids (SCFAs)‐producing bacteria and an increase in putative gut pathobionts. SCFAs‐producing bacteria may vary above or below an "optimal range," causing imbalances. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, increased Bifidobacterium and Lactobacillus in the PD gut microbiome may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging.

pharmacology & pharmacy,neurosciences
Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota

Zhao Ran,Ben-Rong Mu,Dong-Mei Wang,Xin-Huang,Quan-Hong Ma,Mei-Hong Lu

DOI: https://doi.org/10.1007/s12035-024-04584-9

IF: 5.682

2024-01-01

Molecular Neurobiology

Abstract:The human gut microbiota is diverse and abundant and plays important roles in regulating health by participating in metabolism and controlling physiological activities. The gut microbiota and its metabolites have been shown to affect the functioning of the gut and central nervous system through the microbiota-gut-brain axis. It is well established that microbiota play significant roles in the pathogenesis and progression of Parkinson's disease (PD). Disorders of the intestinal microbiota and altered metabolite levels are closely associated with PD. Here, the changes in intestinal microbiota and effects of metabolites in patients with PD are reviewed. Potential mechanisms underlying intestinal microbiota disorders in the pathogenesis of PD are briefly discussed. Additionally, we outline the current strategies for the treatment of PD that target the gut microbiota, emphasizing the development of promising novel strategies.
Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism

Wang Wang,Shujun Jiang,Chengcheng Xu,Lili Tang,Yan Liang,Yang Zhao,Guoxue Zhu

DOI: https://doi.org/10.3389/fnagi.2022.976316

IF: 4.8

2022-11-02

Frontiers in Aging Neuroscience

Abstract:Non-motor symptoms (NMS) of Parkinson's disease (PD), such as constipation, sleep disorders, and olfactory deficits, may emerge up to 20 years earlier than motor symptoms. A series of evidence indicates that the pathology of PD may occur from the gastrointestinal tract to the brain. Numerous studies support that the gut microbiota communicates with the brain through the immune system, special amino acid metabolism, and the nervous system in PD. Recently, there is growing recognition that the gut microbiota plays a vital role in the modulation of multiple neurochemical pathways via the "gut microbiota-brain axis" (GMBA). Many gut microbiota metabolites, such as fatty acids, amino acids, and bile acids, convey signaling functions as they mediate the crosstalk between gut microbiota and host physiology. Amino acids' abundance and species alteration, including glutamate and tryptophan, may disturb the signaling transmission between nerve cells and disrupt the normal basal ganglia function in PD. Specific amino acids and their receptors are considered new potential targets for ameliorating PD. The present study aimed to systematically summarize all available evidence on the gut microbiota-derived amino acid metabolism alterations associated with PD.

neurosciences,geriatrics & gerontology,gerontology
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease

Dongming Yang,Deming Zhao,Syed Zahid Ali Shah,Wei Wu,Mengyu Lai,Xixi Zhang,Jie Li,Zhiling Guan,Huafen Zhao,Wen Li,Hongli Gao,Xiangmei Zhou,Lifeng Yang

DOI: https://doi.org/10.3389/fneur.2019.01155

IF: 3.4

2019-11-06

Frontiers in Neurology

Abstract:It is well-recognized that the gut microbiota (GM) is crucial for gut function, metabolism, and energy cycles. The GM also has effects on neurological outcomes via many mechanisms, such as metabolite production and the gut-brain axis. Emerging evidence has gradually indicated that GM dysbiosis plays a role in several neurological diseases, such as Parkinson's disease (PD), Alzheimer's disease, depression, and multiple sclerosis. Several studies have observed that PD patients generally suffer from gastrointestinal disorders and GM dysbiosis prior to displaying motor symptoms, but the specific link between the GM and PD is not clearly understood. In this review, we aim to summarize what is known regarding the correlation between the GM and PD pathologies, including direct, and indirect evidence.

neurosciences,clinical neurology
Gut microbiota from patients with Parkinson's disease causes motor deficits in honeybees

Jiaqi Zeng,Yiyuan Li,Jingshuang Yan,Ruqi Chang,Mengqi Xu,Guanzhou Zhou,Jie Meng,Di Liu,Zhiqi Mao,Yunsheng Yang

DOI: https://doi.org/10.3389/fmicb.2024.1418857

IF: 5.2

2024-07-13

Frontiers in Microbiology

Abstract:Objective: Parkinson's disease (PD) is possibly caused by genetic factors, environmental factors, and gut microbiota dysbiosis. This study aims to explore whether the microbiota contributes to the behavior abnormalities of PD. Methods: We transplanted gut microbiota from patients with PD or healthy controls (HC) into microbiota-free honeybees. We also established two more groups, namely the rotenone (ROT) group, in which PD-like symptoms of honeybees were induced by rotenone, and the conventional (CV) group, in which honeybees were colonized with conventional gut microbiota. The climbing assay was performed to assess the motor capabilities of honeybees. Histopathological examination was conducted to evaluate the integrity of gut mucosa. Tyrosine hydroxylase (TH) gene expression levels and dopamine (DA) concentrations in the brain were also examined. Additionally, metagenomics and full-length 16S rRNA analyses were performed to identify alterations in gut microbiota profiles, both in PD patients and honeybees. Results: Honeybees in the PD and ROT groups exhibited slower climbing speeds, downregulated TH gene expression, and impaired gut barriers. Both the HC and PD groups of honeybees successfully harbored a portion of gut microbiota from corresponding human donors, and differences in microbial composition were identified. Morganella morganii and Erysipelatoclostridium ramosum exhibited significantly increased relative abundance in the HC group, while Dorea longicatena , Collinsella aerofaciens , Lactococcus garvieae , Holdemanella biformis , Gemmiger formicilis , and Blautia obeum showed significantly increased relative abundance in the PD group. Functional predictions of microbial communities in the PD group indicated an increased synthesis of hydrogen sulfide and methane. Conclusion: A novel PD model was induced in honeybees with rotenone and gut microbiota from PD patients. This study linked PD-related behaviors to altered gut microbiota, highlighting a potential gut microbiota-brain axis involvement in PD pathogenesis. We identify previously unrecognized associations of Dorea longicatena , Collinsella aerofaciens , Lactococcus garvieae , Holdemanella biformis , Gemmiger formicilis , and Blautia obeum with PD. Additionally, pathways related to hydrogen sulfide and methane synthesis have been previously suggested as potential contributors to the development of PD, and our research further supports this hypothesis.

microbiology

Geriatrics photo quiz. Coronary Occlusion.

Multi-Omics Integration in Mice With Parkinson’s Disease and the Intervention Effect of Cyanidin-3-O-Glucoside

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease

Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease

Development of a Telemedicine model with low cost portable tool kit for remote diagnosis of rural people in Bangladesh

MPTP Induced Parkinson's Disease in Mouse: Potential Association Between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis.

Maximizing communication opportunity for collaborative spectrum sensing in cognitive radio networks

Identification of gut metabolites associated with Parkinson's disease using bioinformatic analyses

Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Microbial Biomarker Discovery in Parkinson’s Disease Through a Network-Based Approach

Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance

Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease

Cross-Sectional Study on the Gut Microbiome of Parkinson’s Disease Patients in Central China

Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Female adolescents at high, moderate, and low risk of exposure to HIV: differences in knowledge, beliefs, and behavior.

Gut bacterial profiles in Parkinson's disease: A systematic review

Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota

Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism

The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease

Gut microbiota from patients with Parkinson's disease causes motor deficits in honeybees